Confronto
LL-37 vs. Bremelanotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
597562-32-8
189691-06-3
Peso molecolare
4493.33 g/mol
1025.18 g/mol
Emivita
nessun dato
2.7 h
Sequenza
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMeccanismo d'azione
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
1
5
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
0
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between LL-37 and Bremelanotide?
- LL-37 is classified as "Ricerca (altro)", while Bremelanotide is classified as "Ricerca (altro)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Bremelanotide: Synthetic cyclic heptapeptide acting as a non-selective melanocortin-receptor agonist. FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in pre-menopausal women. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Bremelanotide?
- The highest available evidence level is "Studio sull'uomo" for LL-37 and "RCT sull'uomo" for Bremelanotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Bremelanotide in Germany and the United States?
- Germania: LL-37 — Solo ricerca, Bremelanotide — Non approvato. Stati Uniti: LL-37 — Solo ricerca, Bremelanotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.